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SUMMARY
Tumor-infiltrating CD8 T cells were found to frequently express the inhibitory receptor NKG2A, particularly in immune-reactive environments and after therapeutic cancer vaccination. High-dimensional cluster analysis demonstrated that NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. To examine whether NKG2A represented an adaptive resistance mechanism to cancer vaccination, we blocked the receptor with an antibody and knocked out its ligand Qa-1 b , the conserved ortholog of HLA-E, in four mouse tumor models. The impact of therapeutic vaccines was greatly potentiated by disruption of the NKG2A/Qa-1 b axis even in a PD-1 refractory mouse model. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. These findings indicate that NKG2A-blocking antibodies might improve clinical responses to therapeutic cancer vaccines.
INTRODUCTION
Checkpoint blockade therapy has shown impressive results in metastasized malignant disease, including melanoma, lung, colon, and bladder carcinoma (Topalian et al., 2015) . This form of immunotherapy operates via relief of inhibiting signals through immune receptors CTLA-4 and PD-1 on immune cells, reinvigorating a tumor-rejection response (Tumeh et al., 2014; Gubin et al., 2014) . Therapeutic cancer vaccines, however, have not yet made a major impact, but are starting to reach clinical practice now that the platforms are optimized and tumor-specific antigens are targeted. Currently, their clinical efficacy is limited to precancerous lesions and patients with minimal residual disease (van der Burg et al., 2016; Melief et al., 2015) . Experiments in mouse tumor models demonstrated that cancer vaccines do lead to infiltration of antigen-specific immune cells, but cancers escape due to a plethora of immune suppression mechanisms thereby curtailing full tumor-rejection (van der Burg et al., 2016; Klebanoff et al., 2011) .
One of the emerging suppressive factors in human cancers is the molecule HLA-E, which is a non-classical MHC class I protein. HLA-E is ubiquitously expressed at low levels, but very high expression can be found on trophoblasts and ductal epithelial cells in immune-privileged tissues like placenta and testis, respectively. In cancers, HLA-E is frequently overexpressed compared to their non-transformed counterparts, including melanoma and carcinomas of lung, cervix, ovarium, vulva, and head/neck (Talebian Yazdi et al., 2016; Gooden et al., 2011; van Esch et al., 2014; Seliger et al., 2016; Andersson et al., 2015; Silva et al., 2011) . The physiological function of HLA-E is to present ''self'' peptides derived from other HLA class I molecules (DeCloux et al., 1997; Kraft et al., 2000; O'Callaghan et al., 1998) and to limit autoimmune reactivity. Peptide/HLA-E complexes are recognized by the heterodimeric receptor NKG2A/ CD94 that transduce inhibiting signals after engagement (Braud et al., 1998 (Braud et al., , 2003 Malmberg et al., 2002; Le Dré an et al., 1998) . This inhibiting immune receptor is expressed by cytotoxic lymphocytes, such as natural killer (NK) cells and CD8 T cells that are thereby equipped with the capacity to sense the level of ''self'' MHC class I on target cells (Anfossi et al., 2006; Braud et al., 1998; Malmberg et al., 2002) . Other CD94-comprising heterodimers, such as with NKG2C and NKG2E, can also bind to HLA-E complexes but with much lower affinity (Snyder et al., 2008; Brooks et al., 1997; Kaiser et al., 2005) .
We and others reported a negative correlation of HLA-E on the overall survival of cancer patients (Talebian Yazdi et al., 2016; Gooden et al., 2011; van Esch et al., 2014; Seliger et al., 2016; Andersson et al., 2015; Silva et al., 2011) ; in particular, the beneficial effect of high CD8 T cell counts within tumor was mitigated by high protein expression of HLA-E (Talebian Yazdi et al., 2016; Gooden et al., 2011) . These findings suggested that NKG2A receptor expression on tumor-infiltrating lymphocytes might hamper their function by interaction with HLA-E in the microenvironment. In our current study, we demonstrate that NKG2A expression is promoted by an immune-reactive profile, and therapeutic cancer vaccines strongly induce this inhibitory receptor on CD8 T cells. Blockade of NKG2A, or genetic knockdown of the HLA-E ortholog Qa-1 b in four different murine tumor models turned cancer vaccines into effective therapies.
RESULTS
Expression of the Inhibiting NKG2A Receptor Is Associated with Worse Clinical Outcome Expression of NKG2A and its co-receptor CD94 was investigated in patients affected by head and neck squamous cell carcinoma (HNSCC). Peripheral blood mononuclear cells (PBMC) and tumor-infiltrating lymphocytes (TIL) from carcinomas of different anatomical sites, including oral cavity, larynx, and oropharynx were ex vivo analyzed by flow cytometry. NKG2A/ CD94 surface co-expression was observed on the majority of tumor-infiltrating natural killer (NK) cells and up to 50% of CD8 T cells but was hardly found on CD4 T cells (Figures 1A and 1B) . In contrast, matched PBMC samples of these patients only showed expression on NK cells ( Figure 1B ). Quantitative RNA sequencing (RNA-seq) analysis on sorted lymphocyte subsets confirmed this finding ( Figure S1A ). NKG2A is generally expressed by a majority of NK cells but is selectively expressed within the tumor environment by CD8 T cells.
To investigate if the expression of NKG2A on CD8 T cells was related to their activation status in HNSCC, we made use of the presence of human papillomavirus type 16 (HPV16), which is the causing agent of approximately half of the oropharyngeal subtype of HNSCC. T cell immune reactivity against the HPV16 oncoproteins E6 and E7 (HPV-IR) was assessed in short-term expanded tumor-infiltrating lymphocytes (Welters et al., 2018) . Interestingly, HPV-negative tumors and HPV16-positive tumors lacking T cell immune reactivity to HPV antigens (HPV-IR À ) harbored much lower frequencies of NKG2A + CD8 T cells than HPV-induced carcinomas that did harbor HPV16-directed T cell reactivity (HPV-IR + ) ( Figure 1C ). These data suggested that NKG2A expression on CD8 T cells is predominantly present in immune-reactive tumors. Frequencies of NKG2A + NK cells were equal in these three groups, again demonstrating the constitutive nature of NKG2A expression in these innate immune cells and the induced nature on CD8 T cells. Of note, proportions of NKG2A + CD8 + cells were not affected by the short-term expansion protocol, as similar frequencies were observed in paired samples that could also be tested directly ex vivo (Figure S1B) . These data suggested that activation of tumor-specific T cells in the local environment can induce expression of the inhibitory receptor NKG2A.
Functional consequences of NKG2A expression was then examined using quantitative RNA-seq data of 75 HPV16 + HNSCC in the publicly available TCGA database (Cancer Genome Atlas Network, 2015) . High transcript levels of the CD8 gene correlated with good prognosis ( Figure 1D ). However, high co-expression of KLRC1, which encodes NKG2A, neutralized this clinical benefit, marking NKG2A as a negative prognostic factor in these tumors. Similar observations were made in the interaction analyses for CD8 and the non-classical HLA molecule HLA-E, which is the functional ligand of the NKG2A receptor ( Figure 1D ). In addition, comparable survival benefit was found for those tumors with the combinations of the NK cell marker NCR1 and KLRC1 or HLA-E ( Figure 1D ). Finally, HPVnegative HNSCC, which are generally less well infiltrated by T cells and that display a worse clinical outcome, did not show these immune gene correlations ( Figure S1C ) (Ang et al., 2010; Welters et al., 2018) . Together, these data suggested a potential negative role of the NKG2A/HLA-E axis via CD8 T cells and NK cells in HPV-induced head and neck cancer.
CD8 T Cells that Express NKG2A Belong to CD103 + Tissue-Resident Early Effector Cells We then investigated the characteristics of tumor-infiltrating NKG2A + CD8 T cell subset and compared this with their NKG2A-negative counterparts within the same HNSCC biopsies. Co-expression analyses with other immune checkpoints demonstrated a high frequency of PD-1-and TIGIT-positive T cells irrespective of their NKG2A status ( Figure 2A ). The LAG-3 and CTLA-4 receptors were expressed at lower frequencies by T cells and more frequent on NKG2A + CD8 T cells ( Figure 2A ). In another set of patients with oropharyngeal carcinoma subtype of HNSCC, the proportions of PD-1 and TIM3 expressing cells were similar between NKG2A + and NKG2A À T cell subsets ( Figure S1D ). Thus, expression of NKG2A seemed to be independent of most other inhibitory checkpoint receptors. Examination of known T cell differentiation markers revealed that virtually all tumor-infiltrating NKG2A + CD8 T cells expressed CD45RO, but not CCR7 nor KLRG1, indicative of early effector cells ( Figure 2B ). Importantly, the pool of NKG2A À CD8 T cells in the same tumor samples contained many more cells belonging to a central memory phenotype as well as to end-stage KLRG1-positive effector phenotypes, like short-lived effector cells (SLEC) and terminally differentiated effector cells (TEMRA). These NKG2A À CD8 T cells indeed produced interferon (IFN)-g more frequent upon mitogen stimulation ex vivo, in line with their end-stage effector cell phenotype, whereas the NKG2A + subset was more associated with the cytolytic proteins perforin and granzyme B ( Figure S1E ). Analysis of the surface adhesion molecule CD103, which is functionally associated with tissue-residency, showed that the vast majority of intratumoral NKG2A + CD8 T cells were positive (Figures S1F and S1G). To gain a detailed insight in the T cell and NK cell subsets associated with NKG2A expression, we embarked on a 36-parameter mass-cytometer (CyTOF) platform. Cluster analyses were first visualized with vi-SNE plots on pregated CD3 + CD8 + cells. Strikingly, all NKG2A-expressing T cell subsets clustered closely together in all six carcinomas . NKG2A was apparently an important discriminating marker among the other 33 mainly lymphocyte-associated molecules. In contrast, NKG2A + clusters of NK cells were more dispersed in these samples ( Figures S2F-S2L ). The CyTOF analysis confirmed our flow cytometry findings on NKG2A + T cells, in that this subset did not display an end-stage effector or central memory phenotype due to the selective absence of CCR7, CD127, KLRG1, and CD45RA ( Figures 2C and 2D) . Figure S1 . Lack of CD27 and CD28 co-stimulatory receptors further corroborated this notion ( Figures 2C and 2D ). Furthermore, this subset preferentially expressed a number of receptors also found on tumor-infiltrating NK cells, as well as the interleukin (IL)-2 receptor chains CD25 and CD122 ( Figure 2D and S2F). Finally, strong preferential co-expression of CD103 in these six carcinomas suggested that NKG2A demarks an early effector tissue-resident CD8 T cell subset ( Figures 2C and 2D ).
Therapeutic Vaccination Induces NKG2A on TumorInfiltrating CD8 T Cells We aimed to determine the impact of NKG2A expressed by tumor-infiltrating immune cells on the function of these cells and, consequently, tumor outgrowth. We therefore exploited a mouse model for HPV16-induced carcinoma in which we previously developed an effective therapeutic vaccine based on synthetic long peptides (van der Sluis et al., 2015) . Vaccination with a long peptide induces a strong anti-tumor CD8 T cell response leading to intratumoral T cell influx and immune-mediated regressions of the carcinomas (van der Sluis et al., 2015) . After this temporal remission phase, most tumors rebound from day 20 onward and show progressive tumor outgrowth (Figures 3A and 3B) . Similar to what was seen in human HNSCC samples, NKG2A expression was observed on CD8 T cells and NK cells, but not on CD4 T cells ( Figure 3C ). Importantly, the percentage of NKG2A + CD8 T cells in the tumor was strikingly enhanced after vaccination-induced immune reactivity and increased over time to frequencies over 80% at the tumor relapse phase ( Figure 3D ). Considering the fact that vaccination also resulted in extensively increased numbers of infiltrating CD8 T cells ( Figure S3A ), these NKG2A-positive cells represented the dominant population of immune cells in these immune-activated lesions. In contrast, <5% of NKG2A-expressing CD8 T cells were detected in the spleen of vaccinated tumor-bearing mice ( Figure S3B ), implying a strong selective localization of this receptor in tumors. These data mirrored those from our findings in human oropharyngeal carcinoma samples in that high frequencies of NKG2A-expressing CD8 T cells were predominantly found in tumors harboring immune reactivity in their tumor microenvironment ( Figure 1C ). Frequencies of NKG2A-positive NK cells were stable, like those in human cancer samples, irrespective of therapeutic vaccination ( Figures 3C and 3D ). Importantly, NK cells were dispensable for vaccine-induced tumor regressions ( Figures S3C and  S3D ), whereas we previously demonstrated a crucial role for CD8 T cells in this mouse model (van der Sluis et al., 2015) . Because vaccine-induced tumor remissions are not durable in this model, we additionally investigated expression of the established inhibitory receptors PD-1 and TIM-3 at the tumor relapse phase with flow cytometry ( Figure S3E ). Consistent with our findings in HNSCC patients, we did not find a correlation between NKG2A expression on CD8 T cells with other inhibitory receptors in untreated tumors ( Figure 3E ). Vaccination promoted a high level of co-expression, especially at later time points ( Figure 3E) . A stable receptor profile was again observed for NK cells, and an increase in the TIM-3 + subset of CD4 T cells was found (Figure 3E) . Together, we concluded that expression of inhibitory receptors is highly dynamic on intratumoral CD8 T cells and associated with loss of tumor control.
NKG2A Blockade, but Not PD-1 Blockade, Delays Tumor Relapse after Peptide Vaccination The results on expression of inhibitory receptors on tumor-infiltrating lymphocytes prompted us to provide PD-1 or NKG2A-blocking antibodies in the TC-1 mouse model from day 18 onward, which marks the time of relapse. Unexpectedly, we did not observe any advantage of PD-1 blocking antibodies in combination with the vaccine, even though this receptor was detected on T cells in the tumors ( Figures 4A-4C and S4A ). In contrast, blockade of NKG2A profoundly improved the tumor response ( Figures 4D-4F and S4B). The progression-free survival time doubled in mice that received the NKG2A blockade and, moreover, nearly all mice showed a complete or partial regression response according to RECIST criteria, resulting in a significant delayed tumor outgrowth ( Figures 4D-4F ). NKG2A blockade alone was not effective in this tumor model ( Figure 4F ), suggesting a requirement for an inflammatory tumor environment, such as ignited by peptide vaccination, for its therapeutic benefit. We confirmed that the applied mouse version of the rat monoclonal antibody (mAb) anti-NKG2A, 20d5 (Vance et al., S4D ). NKG2A blockade seemed to enhance early immune cell influx in the tumor ( Figure S4E ) and to increase the co-expression of CD94, PD-1, and TIM-3 on CD8 T cells in the tumor at the early relapse phase ( Figures S4F and S4G ). This was not found for NK cells (Figures S4F and S4G) . These results indicated an empowering impact of NKG2A blockade during relapse on immune-mediated control of virus-induced tumors.
To substantiate these results with non-viral tumors, we examined NKG2A blockade in the MC38 colon carcinoma model ( Figure S5 ). Therapeutic vaccination with point-mutated neoantigenic peptides and CpG as adjuvant resulted in detectable peptide-specific CD8 T cells in blood, but hardly prevented tumor outgrowth ( Figures S5A-S5C ). In contrast to the TC-1 tumor model, frequencies of NKG2A + CD8 T cells in the tumors were already high in untreated tumors and not further increased upon vaccination ( Figure S5D ). Despite that all mice eventually succumbed due to progressive tumor outgrowth, survival time for NKG2A blockade combination therapy was significantly enhanced compared to vaccination alone (Figures S5B and S5C) . Together, these results suggested that NKG2A restrains efficacy of tumor control by CD8 T cells after vaccination.
Inflammation Induces Qa-1 Expression on Tumor Cells
The heterodimer receptor NKG2A/CD94 selectively binds the non-classical MHC molecule Qa-1 b , the mouse ortholog of HLA-E. Although Qa-1 b is ubiquitously expressed in most body tissues, like conventional MHC class I, the protein cell surface display is rather low in most epithelial cell types. Protein expression is hardly detectable on in vitro cultured tumor cell lines, whereas antigen-presenting cells, like dendritic cells and B cells, express high levels (Doorduijn et al., 2018) . We therefore examined if Qa-1 b on host cells was a requisite for NKG2A blockade therapy and performed treatment experiments in Qa ( Figures 5C and S6E ). RMA lymphoma cells displayed constitutive high levels, but these were also increased by IFN-g. Interestingly, several other mouse epithelial tumor cell lines responded comparably to IFN-g, except MC38, which did not respond to this cytokine in vitro, but still highly upregulated Qa-1 b after transplantation in mice ( Figure S5E ), suggesting that other environmental cues were involved.
Genetic Knockdown of Qa-1 b in Tumors Enhances Peptide Vaccination Therapy Finally, we generated genetic knockdown cell lines for the gene encoding Qa-1 b using CRISPR-Cas9 gene-editing ( Figure S7A ). In the TC-1 model, Qa-1 b -deficient tumor cells were more sensitive for peptide vaccination-induced remission (Figures 6A, 6B, and S7B-S7D). Tumor regressions were deeper and were longer maintained, leading to longer progression-free survival and smaller tumors at later time points. Peptide vaccination in the RMA lymphoma model was also significantly better for Qa-1 b -deficient cells compared to wild-type tumor cells (Figures 6C, 6D, S7E, and S7F) . Approximately half of the mice successfully eradicated their lesions, and outgrowth in the other mice was clearly delayed. Finally, deletion of Qa-1 b in B16 melanoma model also rendered the tumor cells more vulnerable to vaccine-induced T cell responses ( Figures 6E, 6F , S7G, and S7H).
The vaccine-induced CD8 T cell responses were comparable in mice bearing wild-type or Qa-1 b -deficient tumors ( Figures  S7C, S7F , and S7H), indicating that the systemic anti-tumor immunity was the same, but the immune cells exhibited stronger tumoricidal effects.
NK Cells Are Dispensable for the Enhanced Peptide Vaccination Effect
We argue that the improved survival benefit in these mouse models was mainly T cell-mediated, since CD8 T cells are essential for the therapeutic effect in these models (Ossendorp et al., 1998; van der Sluis et al., 2015; Ly et al., 2010 Ly et al., , 2013 and cognate peptide antigens were required in the vaccines (Figures 6E and 6F, ''adjuvant alone,'' and 7A-7C, ''control vaccinated''). Moreover, cancer vaccines strongly upregulated the expression of NKG2A on CD8 T cells but not NK cells. Finally, depletion of NK cells did not abolish the beneficial effect on survival ( Figures  7B, 7C , S3C, and S3D).
Taken together, these data imply an important restraining role of the NKG2A/Qa-1 b axis for therapeutic cancer vaccines, medi- 
DISCUSSION
Our study revealed a negative feedback of cancer vaccines in the tumor microenvironment via induction of the inhibitory receptor NKG2A on CD8 T cells and the increased expression of its ligand on tumor cells. Interruption of NKG2A signaling by blocking antibodies or genetic deletion of the gene coding for its ligand Qa-1 b , the mouse ortholog of HLA-E, strongly potentiated the efficacy of cancer vaccines in four mouse tumor models. The immune inhibitory NKG2A/HLA-E axis is likely to have a similar role in cancer patients as we found NKG2A to be expressed on a sizeable fraction of head and neck tumor-reactive CD8 T cells. Expression of the NKG2A by human tumor-infiltrating lymphocytes was previously described in untreated samples of other cancer types (Sheu et al., 2005; Gooden et al., 2011; van Esch et al., 2015) . Importantly, we now show that the inhibiting NKG2A/HLA-E axis constitutes an adaptive resistance mechanism in response to (vaccine-induced) activated T cell immunity in the microenvironment (Sharma et al., 2017) . This counter response by tissues plausibly protects from overwhelming immune-mediated damage via cytolytic killer cells, including CD8 T cells and NK cells, and high local release of IFNg (Zhou et al., 2008) . Similar findings have been reported for the ligand of PD-1, which is also induced by interferons (Abiko et al., 2015) .
Although the NKG2A/HLA-E axis was originally described to impact NK cell function, we argue that these innate lymphocytes only marginally contribute to our combination protocol of therapeutic vaccines and blockade of this receptor. First, depletion of NK cells did not affect the tumor control. Second, vaccination protocols with control antigens failed to induce tumor-specific CD8 T cells and tumor control, despite allowing NK cell activation via adjuvant. Third, our earlier work demonstrated that these cancer vaccines depended on CD8 T cells (van der Sluis et al., 2015; Ossendorp et al., 1998; Ly et al., 2010 Ly et al., , 2013 . Finally, this central role of NKG2A on CD8 T cells has been reported in mouse models of viral infections (Zhou et al., 2008; Rapaport et al., 2015; Ely et al., 2014; Moser et al., 2002) . However, this does not exclude a contribution of NK cells to NKG2A blockade therapy in the context of checkpoint therapy, as others demonstrated in two lymphoma models that the responses were partly abolished when NK cells were depleted (André et al., 2018 [ 
this issue of Cell]).
One important difference with the conventional PD-1 and CTLA-4 immune inhibitory checkpoints is the lineage-selective expression of NKG2A, which is predominantly present on cytolytic lymphocytes. In contrast to PD-1 and CTLA-4, NKG2A is virtually absent on CD4 T helper cells and the small subset that did stain in our set of human head and neck carcinomas might represent cytotoxic T helper cells, which represent a distinct subset with dedicated precursors (Patil et al., 2018) . Display of NKG2A on NK cells was frequently found, especially in the tumor environment, and was hardly influenced by cancer vaccines or immune-reactive environments. In contrast, these conditions did lead to higher proportions of NKG2A + CD8 T cells in the tumor, implying a dynamic regulation in these lymphocytes. The observation that high frequencies of NKG2A + CD8 T cells were mainly found in cancer samples of patients and mice with active local immunity, suggests that NKG2A expression reflects recent activation, which is in line with literature showing that TCR triggering is required for the induction of NKG2A on CD8 T cells (Gunturi et al., 2005) . Our co-expression analyses of inhibitory receptors on CD8 T cells revealed that NKG2A display did not parallel that of PD-1, TIGIT, TIM-3, and LAG-3. The other inhibitory receptors were approximately evenly distributed among NKG2A-positive and -negative subsets. Interestingly, PD-1 blockade did not improve vaccination therapy in our TC1 model, whereas NKG2A blockade was successful (Figure 4 ). These findings provide insight in the distinct cellular mechanisms underlying NKG2A versus PD-1 blockade therapy, as they might target different T cell subsets. Indeed, such differences in mode-of-action were described for the two Food and Drug Administration (FDA)-approved antibodies to CTLA-4 and PD-1 (Wei et al., 2017). PD-1/PD-L1 blockade therapy is a first line treatment in an increasing number of cancer types, and therefore combination with NKG2A mAb was tested in the PD-1/PD-L1-responsive MC38 mouse colon tumor model. Intriguingly, the addition of NKG2A mAb did not improve the therapeutic efficacy of PD-1 or PD-L1 mAbs, in contrast to addition to a synthetic peptide vaccine in this model ( Figure S5 ). The lack of therapeutic synergy between NKG2A and PD-1/PD-L1 in this colon model is not fully understood yet but might be related to the fact that these inhibitory receptors are exhibited on an overlapping subset of intratumoral CD8 T cells and that NK cells are dispensable. Importantly, the combination of PD-L1 and NKG2A blockade was shown to be successful in two mouse lymphoma models (A20 and RMA.Rae1), which were controlled by CD8 T cells in conjunction with NK cells (André et al., 2018) . The additional employment of anti-NKG2A-enabled NK cells might explain the strong efficacy of this NKG2A and PD-L1 checkpoint combination in these lymphoma models.
The NKG2A targetable T cell subset in cancers was positive for the tissue-resident marker CD103 and multiple NK-related receptors and markers of early effector cells (Figure 2 ). NKG2A expression was found to be inducible in T cells by TCR triggering in combination with tissue-released cytokines like IL-15 and transforming growth factor b (TGF-b) (Gunturi et al., 2005; Bertone et al., 1999; Sheu et al., 2005) . Indeed, NKG2A expression was recently also reported on T cells from normal lung tissues, where they were poised for rapid responsiveness (Hombrink et al., 2016) . In combination with the fact that CD103 + T cells have been associated with good clinical prognosis in multiple cancers (Webb et al., 2014a (Webb et al., , 2014b Komdeur et al., 2017; Wang et al., 2016; Bö smü ller et al., 2016) , these findings portray the NKG2A-positive CD8 T cell subset as tissue-residing lymphocytes with immediate effector functions kept in check by their inhibiting receptors, such as NKG2A.
The humanized IgG4 antibody monalizumab, specific for NKG2A, is currently under evaluation in several clinical trials in combination with other conventional cancer treatments. Recent clinical data suggest that NKG2A blockade might enhance the cetuximab-induced responses in patients with head-and neck carcinomas (André et al., 2018) and we anticipate that it will also empower therapeutic cancer vaccines.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
HNSCC patient cohort (TCGA) Gene expression profiles (RNA-seq) and clinical data for head and neck squamous cell carcinoma (n = 419) from The Cancer Genome Atlas (TCGA) were downloaded via the GDC data portal (https://portal.gdc.cancer.gov/). In this cohort, 75 HPV16 positive samples had been detected. Detail on data generation is available in the original study (Cancer Genome Atlas Network, 2015) .
HNSCC patient cohort (Nashville) Samples were obtained from head and neck squamous cell carcinoma patients undergoing surgery after signing informed consent. Collection and use of human tissues was approved by the medical ethical review board of Vanderbilt University Medical Center IRB #030062, NCT00898638.
OPSCC patient cohort (LUMC)
Patients with histological confirmed oropharyngeal squamous cell carcinoma (OPSCC), which is a subset of HNSCC, were included after signing informed consent. The OPSCC patients were part of a larger observational study (P07-112) investigating the circulating and local immune response in patients with head and neck cancer (Heusinkveld et al., 2012) This study was approved by the local medical ethical committee of the Leiden University Medical Center (LUMC) and in agreement with the Dutch law. The patients received the standard-of-care treatment which could consist of surgery, radiotherapy, chemotherapy, treatment with monoclonal antibody or combinations hereof.
CxCa patient cohort (LUMC)
Patients with histological confirmed cervical carcinoma (CxCa) were included after signing informed consent. The CxCa patients were enrolled in the CIRCLE study, which investigates cellular immunity against cervical lesions (de Vos van Steenwijk et al., 2010; Piersma et al., 2008) . This was approved by the local medical ethical committee of the Leiden University Medical Center (LUMC) and in agreement with the Dutch law. The patients received the standard-of-care treatment which could consist of surgery, radiotherapy, chemotherapy, treatment with monoclonal antibody or combinations hereof.
Mice C57BL/6 mice were purchased from Charles River Laboratories (L'Arbresle, France). Qa-1 bÀ/À mice that harbor a targeted mutation of the H2-T23 gene (The Jackson Laboratory stock no. 007907), were kindly provided by Dr. M. Vocanson (Lyon, France) and bred in our own facility. T cell receptor (TCR) transgenic mice containing gp100 25-33 /H-2D b specific receptors (Overwijk et al., 2003) were a kind gift of Dr. N.P. Restifo (NIH, Bethesda, USA) and were bred to express the congenic marker CD45.1 (Ly5.1). All mice were housed in individually ventilated cages, maintained under specific pathogen-free conditions and used at 6-12 weeks of age. All mouse experiments were controlled by the animal welfare committee (IvD) of the Leiden University Medical Center and approved by the national central committee of animal experiments (CCD) under the permit number AVD116002015271, in accordance with the Dutch Act on Animal Experimentation and EU Directive 2010/63/EU.
Mouse tumor cell lines
The tumor cell line TC-1 expresses the HPV16-derived oncogenes E6 and E7 and activated Ras oncogene and were a gift from T.C. Wu (John Hopkins University, Baltimore, USA). The B16F10 melanoma cell line was purchased from the American Type Culture Collection (ATCC-CRL6475). The RMA cell line is a mutagenized derivative of the Rauscher MuLV-induced T cell lymphoma RBL-5. The MC38 cell line is a chemically induced colon adenocarcinoma. All cells were derived from C57BL/6 mice and cultured in Iscove's modified Dulbecco's medium (IMDM; Invitrogen) supplemented with 8% FCS (GIBCO), glutamine and 2% penicillin/streptomycin (complete medium) at 37 C in a humidified atmosphere containing 5% CO 2 . Cell lines were assured to be free of rodent viruses and Mycoplasma by regular PCR analysis. Authentication of the cell lines was done by antigen-specific T cell recognition and cells of low passage number were used for all experiments.
METHOD DETAILS
Survival plots HNSCC patient cohort (TCGA) The overall survival time was defined using the latest information. For survival analysis, the patients were dichotomized based on gene expression levels. The median cutpoints were determined to stratify patient into two groups (Hi and Lo). Kaplan Meier estimators of survival were used to visualize the survival curves. The log-rank test was used to compare overall survival between patients in different groups. p values for the HiHi, HiLo, LoHi, and LoLo gene combination analysis were corrected for multiple testing using the Benjamini-Hochberg method. All analyses were performed using the statistical software environment R (package survival).
Flow cytometry HNSCC patient cohort (Nashville) Fresh tumor samples were processed using miltenyi biotec human tumor dissociation kit and the Miltenyi GentleMACS Octo dissociator following manufacturer's instructions. PBMC were collected from blood using Ficoll-Paque Plus, following manufacturer's instruction. Single cell suspensions were stained and analyzed by flow cytometry the same day the samples were collected using a BD FACSCelsta. The monoclonal antibodies used were against TIGIT (A15153G), CTLA-4 (BNI3), CCR7 (G043H7), CD127 (A019D5), CD45RO (UCHL1) and KLRG-1 (14C2A07). For ICS staining single cells suspensions were incubated with PMA/ionomycin (Cell stimulation cocktail, Invitrogen) and monensin (BioLegend) for 4 hr at 37 C. Following activation, the cells were surface stained and then fixed for 15 min with IC fixation buffer (eBioscience). Following fix, cells were permeabilized with perm buffer (eBioscience) and intracellularly stained for IFN-g (4S.B3), Perforin (B-D48) and Granzyme B (GB11).
Flow cytometry OPSCC patient cohort (LUMC)
Blood and tumor tissue samples were taken prior to treatment and handled as described previously (Welters et al., 2018) . Peripheral blood mononuclear cells (PBMCs) and tumor infiltrating lymphocytes (TILs) were stored until use. HPV typing was performed on former fixed paraffin embedded (FFPE) tumor sections at the department of pathology at the LUMC. HPV-specific immune reactivity of TILs was determined in a 5-day proliferation assay (Welters et al., 2018) : HPV type 16 negative HNSCC (HPV-, n = 5), HPV16-positive tumors without ex vivo immune reactivity (IR-, n = 5) and HPV16-positive tumors displaying ex vivo immune reactivity to HPV16 (IR+, n = 8). The phenotype and composition of dispersed OPSCC and expanded TILs was analyzed by flow cytometry.
The monoclonal antibodies used were against CD3 (UCHT1), CD8 (SK1), CD56 (B159), CD4 (RPA-T4), CD94 (FAB1058F), TIM3 (F38-2E2), CD279/PD1 (EH12.2H7) and CD159a/NKG2A (Z199) from BD, R&D, BioLegend or Beckman-Coulter.
CyTOF analysis CxCa patient cohort (LUMC)
The phenotype of dispersed cervix carcinoma samples was analyzed by high dimensional single cell time-of-flight mass cytometry (CyTOF) of 34 markers as described (Welters et al., 2018) , with NKG2A-142 Nd (Z199) replacing the CD34-142 Nd antibody. Cluster analysis was performed independent from NKG2A expression and visualized in tSNE plots of pre-gated CD3 + CD8 T cells. Expression ratios of different markers are based on the mean signal intensity (MSI) between compared populations.
In vivo experiments in mouse tumor models For tumor inoculation, 100,000 TC-1, 100,000 B16F10, 1,000 RMA or 250,000 MC38 tumor cells were injected s.c. in the flank of mice in 200 mL PBS/0.1% BSA. Tumors were measured twice a week with a calliper. When a palpable tumor was present, mice were split into groups with similar tumor size and were treated with immunotherapy. Mice were sacrificed when tumors reached a volume of 1000 mm 3 . TC-1 tumors were treated with a peptide vaccine on day 8 after tumor inoculation with 150 mg of the HPV16 E7 43-77 peptide (GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR) emulsified at a 1:1 ratio with Incomplete Freunds Adjuvant (IFA; Difco) s.c. in the contralateral flank (van der Sluis et al., 2015) . NKG2A-blocking antibody (MO20D5) was produced by Innate Pharma (Marseille, France) and is an engineered variant of the rat IgG2a anti-mouse NKG2A/C/E (clone 20D5), comprising mouse Ig constant domains with mutations to inactivate Fc receptor and complement binding. Isotype control antibody contained the same modifications. The PD-1 blocking antibody was purchased from BioXCell (clone RMP1-14, InvivoPlus). Antibodies were applied at a dose of 200 mg i.p. or i.v. at days 18, 22, and 29. Vaccine-induced T cell responses were measured by intracellular cytokine staining (ICS) and flow cytometry. Peripheral blood lymphocyte (PBL) samples were collected 6 days after vaccination and incubated overnight with the short HPV16 E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] peptide in the presence of 1 mg/ml GolgiPlug (BD Biosciences). Antibodies to CD8a (53-6.7) and IFN-g (XMG1.2) from Biolegend were used for stainings. For NK cell depletion, mice were injected i.p. with 100 mg of the NK-cell depleting monoclonal antibody clone PK136 (BioXCell, InvivoPlus) on day 7 and then every 3-4 days. Therapy response rates according to RECIST criteria: NR: no response, PR: partial response, defined as a decrease in tumor size, at least 2 consecutive measurements and minimal 30% of lesion, CR: complete response, defined as a complete disappearance of a previous tumor. Progression free survival (PFS) defined as the duration of response from the day that tumor reaches maximum size until the day that tumor exceeds maximum size again.
MC38 tumors were treated with two vaccinations on days 6 and 13 with a mix of 3 peptides, based on the natural elongated sequences of previously published mutant neo-antigens optimized for solubility (Adpgk: PVHLELASMTNMELMSSIVHQ, Dpagt1: EAGQSLVISASIIVFNLLELEGDYR, Reps1: ELFRAAQLANDVVLQIMEL) (Yadav et al., 2014) . Peptides, 50 mg each, were mixed with 20 mg CpG (ODN 1826, Invivogen) and injected s.c. in the tail-base region in 50 mL PBS. To analyze efficacy of vaccination, PBL samples were collected from tail veins at 6 days after the last vaccination. Percentages of vaccine-induced CD8 T cells was determined by peptide-MHC tetramers and flow cytometry. All peptides and tetramers were produced in our own facility. Blocking antibodies to NKG2A (MO20D5) and PD-1 (RMP1-14) were provided i.p. or i.v. at a dose of 200 mg at days 9, 16, 23 and 30.
B16F10 tumors were treated with a combination of adoptive transfer of tumor-specific (pmel) TCR transgenic T cells and peptide vaccination, as described previously (Ly et al., 2010) . Lymphocytes from spleen and lymph nodes of naive CD45.1-positive pmel mice were isolated and enriched for T lymphocytes by nylon wool. Enriched spleen cells (3 3 10 6 cells) were adoptively transferred by injection into the tail vein at day 4. Mice were immunized at day 5 and 12 by s.c. injection of 150 mg peptide comprising the human gp100 20-39 sequence (AVGALKVPRNQDWLGVPRQL) in PBS. 60 mg of Aldara cream containing 5% imiquimod was simultaneously applied on skin at the shaved injection site. At days 12 and 13, 600,000 IU human recombinant IL-2 (Novartis) was supplied. Vaccineinduced pmel T cell responses were measured at day 18 by intracellular cytokine staining (ICS) and flow cytometry. Peripheral blood lymphocyte (PBL) samples were collected 6 days after vaccination and incubated overnight with the 9-mer gp100 25-33 peptide EGSRNQDWL in the presence of 1 mg/ml GolgiPlug (BD Biosciences) using antibodies against CD8a (53-6.7), CD45.1 (A20) and IFN-g (XMG1.2) from Biolegend and analyzed by flow cytometry. RMA tumors were treated with a single vaccination on day 7 with 20 nmol of the Murine Leukemia virus Env-encoded CD4 T cell epitope EPLTSLTPRCNTAWNRLKL and 50 nmol of the Gag-encoded CD8 T cell epitope CCLCLTVFL (Kleinovink et al., 2016) mixed with 20 mg CpG (ODN 1826, Invivogen), in 50 mL PBS s.c. in the tail-base region. Efficacy of vaccination was measured in PBL 7 days after vaccination by peptide-specific intracellular cytokine production after overnight incubation with the peptides in the presence of Golgi-plug (BD Biosciences). Antibodies to CD4 (RM4-5), CD8a (53-6.7) and IFN-g (XMG1.2) were used from Biolegend and analyzed by flow cytometry. For NK cell depletion, mice were injected i.p. with 100 mg of the NK-cell depleting monoclonal antibody clone PK136 (BioXCell, InvivoPlus) on day 7 and then every 3-4 days.
Flow Cytometry on mouse tumor samples For analysis of tumor-infiltrating populations, mice were sacrificed at indicated time points and tumors were harvested, disrupted in small pieces, and incubated with Liberase TL (Roche) in IMDM for 15 min at 37 C. Single-cell suspensions were prepared by mincing the tumors through a 70-mm cell strainer (BD Biosciences). Cells were first incubated with live/dead fixable yellow dead cell stain (Thermo Fisher Scientific, L34959) in PBS for 20 min at room temperature. Subsequently, cells were washed and resuspended in staining buffer (PBS + 0.5% BSA + 0.05% sodium azide) supplemented with 2.4G2 Fc block for 15 min on ice. Subsequently, cells were incubated with monoclonal antibodies for 30 min on ice. Antibodies used were against CD3 (145-2C11), NK1.1 (pk136), CD4 (RM4-5), TIM3 (RMT3-23), CD8a (53-6.7), CD45.2 (104), CD94 (18d3), NKG2A (16a11), PD-1 (RMP1-30) and LAG3 (eBioC9B7W) from BD, BioLegend or eBioscience. Staining of Qa-1 b was performed in a 2 step procedure with biotin-labeled anti-Qa-1 b (clone 6A8.6F10.1A6) followed by streptavidin-APC. Samples were acquired on a BD Fortessa flow cytometer, and results were analyzed using the FlowJo software (TreeStar).
In vitro stimulation of tumor cells Tumor cell lines were plated at day À1 in 24 wells plates at a cell density of 20.000/well in 2 mL of culture medium. At day 0, indicated concentration of recombinant IFN-g (Biolegend) or cell culture supernatants were added to the cells. After 48 hr, cells were harvested and stained with monoclonal antibodies to Qa-1 b (6A8.6F10.1A6), D b (28-14-8) and PDL-1 (MIH5) for 30 min on ice in flow cytometry staining buffer. Fibroblast and tumor cell supernatants were generated by collecting conditioned medium from R1 cells and KPC tumor cells, respectively. Macrophage supernatants were generated from M-CSF mediated bone-marrow derived macrophages stimulated overnight with LPS. Splenocyte supernatant was generated by incubation with 5 mg/ml Concanavalin A (type IV, Sigma C 2010) and 5 ng/ml Phorbol myristate acetate (Sigma P 8139) and collecting supernatants during 3 subsequent days. CD3-negative and -positive cell fractions were generated with mouse CD3ε MicroBead kit (Milteny Biotec). Experiments with blocking antibodies were performed by pre-incubation for 1h with rat anti-mouse IFN-ɣR (CD119) (clone GR-20, BioXcell) or isotype control (clone 2A3, BioXCell) followed by incubation with 1.5% splenocyte supernatants for 24 hr. 
QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis
The non-parametric log-rank test (Mantel-Cox test) was used to compare the survival distribution of groups of patients or mice. Additional statistical methods are stated in the figure legends. In all cases a P-value of 0.05 and below was considered significant (*), p < 0.01(**) and p < 0.001 (***) as highly significant. (legend continued on next page)
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